Sandoz teamed up with RareGen to launch a generic to United Therapeutics’ Remodulin, which pulled in about $500 million in the U.S. last year. More: As Remodulin copies roll, United Therapeutics faces big hit to its top seller Source: fierce
read moreWith Brazil’s economy in tatters and the costs of manufacturing rising, Roche will slowly pull production out of the country, a decision that will cost hundreds of workers their jobs. More: Roche sets clock ticking for Brazil plant and 640
read moreLess than two years after revealing a multimillion-dollar upgrade plan for its plant in Macclesfield, U.K., AstraZeneca is cutting back, slashing almost 100 jobs in what a local union called a “hammer blow” to U.K. manufacturing. More: AstraZeneca to cut
read moreAstraZeneca’s Farxiga just won European approval in Type 1 diabetes, but its prospects in the U.S. are less certain. The FDA’s rejection of Sanofi and Lexicon Pharmaceuticals’ would-be rival Zynquista may serve as an ill omen in Type 1 for
read moreTurns out shareholders aren’t the only ones who have some issues with Bristol-Myers Squibb’s proposed $74 billion Celgene merger. The Federal Trade Commission is taking a closer look at the companies’ psoriasis drugs, both those on the market and those
read moreMerck CEO Kenneth Frazier is dealing with challenges ranging from lawmakers’ criticisms over high drug prices to pressure to find revenue-growth opportunities beyond the company’s immuno-oncology blockbuster Keytruda. But he remains unfazed, thanks to advice his father gave him when
read more© 1994 - 2026 B.M. Pharmaceuticals